Need professional-grade analysis? Visit stockanalysis.com
$31.90M
N/A
N/A
N/A
INmune Bio Inc (INMB) trades on United States in USD. The company is classified in the Healthcare sector under the Biological Products industry. The stock currently trades at $1.38, down 3.50% from the previous close.
Over the past year, INMB has traded between a low of $1.12 and a high of $8.09. The stock has lost 82.8% over this period. It is currently 82.9% below its 52-week high.
INmune Bio Inc has a market capitalization of $31.90M.
INmune Bio Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, which is in Phase II for the treatment of breast cancer. It provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression; and CORDstrom, a cell suspension for intravenous infusion or injection comprising aseptic, allogeneic, and pooled HucMSCs. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.
Side-by-side comparison against top Healthcare peers.